Gain Total Current Assets vs Cash Analysis
GANX Stock | USD 2.50 0.01 0.40% |
Gain Therapeutics financial indicator trend analysis is much more than just examining Gain Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gain Therapeutics is a good investment. Please check the relationship between Gain Therapeutics Total Current Assets and its Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.
Total Current Assets vs Cash
Total Current Assets vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gain Therapeutics Total Current Assets account and Cash. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Gain Therapeutics' Total Current Assets and Cash is 0.95. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Cash in the same time period over historical financial statements of Gain Therapeutics, assuming nothing else is changed. The correlation between historical values of Gain Therapeutics' Total Current Assets and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Gain Therapeutics are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Total Current Assets i.e., Gain Therapeutics' Total Current Assets and Cash go up and down completely randomly.
Correlation Coefficient | 0.95 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Cash
Cash refers to the most liquid asset of Gain Therapeutics, which is listed under current asset account on Gain Therapeutics balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Gain Therapeutics customers. The amounts must be unrestricted with restricted cash listed in a different Gain Therapeutics account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Gain Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gain Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.At this time, Gain Therapeutics' Tax Provision is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 11.3 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 3 M in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 15.5K | 64.2K | 78.1K | 82.0K | Total Operating Expenses | 14.0M | 17.9M | 22.2M | 11.2M |
Gain Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Gain Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gain Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Current Liab | 253.7K | 768.5K | 1.4M | 2.1M | 2.2M | 1.3M | |
Total Current Liabilities | 879.1K | 2.1M | 2.6M | 4.1M | 4.9M | 2.8M | |
Other Liab | 132.2K | 171.6K | 329.5K | 157.6K | 181.2K | 179.3K | |
Net Tangible Assets | (450.0K) | 6.2M | 34.6M | 18.7M | 21.5M | 12.8M | |
Retained Earnings | (3.5M) | (7.0M) | (20.9M) | (38.5M) | (60.8M) | (57.7M) | |
Accounts Payable | 154.4K | 961.5K | 560.5K | 1.6M | 1.3M | 874.7K | |
Other Assets | 11.4K | 63.8K | 53.4K | 48.3K | 55.6K | 41.4K | |
Net Receivables | 44.9K | 66.6K | 113.6K | 103.9K | 242.6K | 254.7K | |
Other Current Assets | 49.8K | 71.0K | 727.8K | 848.9K | 741.6K | 456.7K | |
Other Stockholder Equity | 3.1M | 13.4M | 55.8M | 57.4M | 73.1M | 37.2M | |
Total Current Assets | 429.5K | 9.0M | 37.7M | 21.1M | 17.8M | 15.9M | |
Property Plant Equipment | 219.3K | 552.7K | 1.0M | 144.4K | 166.0K | 157.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gain Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Gain Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Gain Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Gain Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gain Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Gain Stock please use our How to Invest in Gain Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Gain Stock analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Gain Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. If investors know Gain will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gain Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.78) |
The market value of Gain Therapeutics is measured differently than its book value, which is the value of Gain that is recorded on the company's balance sheet. Investors also form their own opinion of Gain Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gain Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gain Therapeutics' market value can be influenced by many factors that don't directly affect Gain Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gain Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.